In Belo Horizonte, Brazil, public health clinics have expanded access to the RSVpreF vaccine for pregnant individuals to protect infants against severe bronchiolitis caused by respiratory syncytial virus (RSV), a leading cause of infant hospitalization worldwide. This expansion, effective this week, aims to reduce seasonal RSV burden by vaccinating expectant mothers between 32 and 36 weeks gestation, enabling passive antibody transfer to fetuses. The initiative aligns with global WHO recommendations following the vaccine’s 2023 FDA approval and demonstrates how maternal immunization strategies can mitigate infant respiratory disease in resource-variable settings.
How Maternal RSV Vaccination Works: The Science of Passive Immunity
The RSVpreF vaccine (marketed as Abrysvo) contains a stabilized prefusion F glycoprotein antigen from RSV subgroups A and B. When administered to pregnant individuals, it stimulates maternal production of neutralizing IgG antibodies that actively transport across the placenta via the FcRn receptor, peaking in fetal circulation by 34–36 weeks gestation. This passive immunization provides critical protection during the infant’s first 90 days of life — the period of highest risk for severe RSV lower respiratory tract infection (LRTI), which can progress to bronchiolitis requiring oxygen support or mechanical ventilation. Unlike active infant vaccination, which faces immunological immaturity challenges before 6 months of age, maternal vaccination leverages the mother’s mature immune system to confer immediate, transient protection.
In Plain English: The Clinical Takeaway
- Getting the RSV vaccine during pregnancy (weeks 32–36) significantly lowers your baby’s chance of getting severe lung infection from RSV in their first three months.
- The vaccine is safe for both mother and fetus, with side effects similar to other routine prenatal shots like Tdap or flu vaccine.
- In Belo Horizonte, free access is now available at expanded public clinics — no private payment or insurance needed.
Real-World Impact: Evidence from Global Trials and Local Implementation
The expansion in Belo Horizonte builds on pivotal Phase III data from the MATISSE trial (NCT04424316), a randomized, double-blind, placebo-controlled study involving 7,358 pregnant participants across 18 countries. Published in the New England Journal of Medicine in 2022, the trial showed maternal RSVpreF vaccination reduced the risk of severe RSV-associated LRTI in infants by 81.8% (96.66% CI: 40.6–96.3) within 90 days of birth and 69.4% (57.7–78.3) through 6 months. Crucially, no imbalances in preterm birth, low birth weight, or neonatal mortality were observed — addressing early safety concerns seen in earlier RSV vaccine candidates. “The MATISSE trial established that maternal immunization is not only effective but maintains a favorable safety profile, making it a cornerstone strategy for preventing infant RSV hospitalization globally,” stated Dr. Kena Swanson, Vice President of Viral Vaccines at Pfizer and lead investigator on the trial, in a 2023 CDC Advisory Committee on Immunization Practices (ACIP) meeting.
Locally, Belo Horizonte’s municipal health secretariat (SMSA) reports that as of April 2026, 72 primary care units now offer the vaccine — up from 41 sites in January — targeting an estimated 28,000 eligible pregnancies annually. This expansion responds to regional RSV seasonality peaks (typically March–August in Brazil’s Southeast) and aims to close equity gaps in access. Unlike the U.S., where Abrysvo is distributed through private obstetric channels with potential cost barriers, Brazil’s SUS (Sistema Único de Saúde) provides the vaccine free at point of service, mirroring England’s NHS approach to maternal pertussis and flu vaccination. However, challenges remain: cold-chain maintenance in tropical climates and vaccine hesitancy fueled by misinformation require ongoing community engagement, as noted by Minas Gerais State Epidemiology Director Dr. Aline Rocha in a recent Revista de Saúde Pública editorial: “Equitable distribution means nothing if communities don’t trust the vaccine — we pair clinic expansion with culturally resonant outreach through faith leaders and agentes de saúde comunitária.”
Geo-Epidemiological Bridging: From Minas Gerais to Global Policy
Brazil’s adoption of maternal RSV vaccination reflects alignment with WHO’s 2023 position paper recommending RSVpreF or maternal nirsevimab (long-acting monoclonal antibody) programs in all countries with seasonal RSV transmission. While the U.S. FDA approved Abrysvo in August 2023 and the EMA followed in January 2024, implementation varies: the U.S. Relies on obstetric provider stocking (potentially creating access deserts), whereas the UK’s NHS integrated it into routine antenatal care by October 2024. In contrast, low-income nations await Gavi funding decisions expected in late 2026 for subsidized rollout. Belo Horizonte’s model — leveraging existing prenatal infrastructure within SUS — offers a replicable framework for middle-income countries seeking to prevent the estimated 3.6 million annual RSV hospitalizations in infants under 6 months globally (WHO, 2023). Notably, the vaccine’s mechanism avoids interfering with live vaccines (e.g., rotavirus) administered at 2 and 4 months, allowing seamless integration into existing infant immunization schedules.
| Metric | Maternal RSVpreF Vaccine Group | Placebo Group | Relative Efficacy (95% CI) |
|---|---|---|---|
| Severe RSV LRTI in infants (0–90 days) | 6 cases (n=3,682) | 33 cases (n=3,676) | 81.8% (40.6–96.3) |
| RSV LRTI requiring medical visit (0–90 days) | 51 cases | 118 cases | 57.1% (40.2–69.5) |
| Preterm birth (<37 weeks) | 4.2% | 4.0% | Not significant |
| Low birth weight (<2,500g) | 7.1% | 6.8% | Not significant |
Contraindications & When to Consult a Doctor
The RSVpreF vaccine is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the formulation, including sucrose or tromethamine. It should be delayed in pregnant individuals experiencing moderate or severe acute illness (with or without fever) until recovery. Minor illnesses, such as mild upper respiratory infection, do not constitute a contraindication. While no evidence suggests risk to breastfeeding infants, lactating individuals may receive the vaccine per ACIP guidance. Pregnant individuals should consult their obstetrician if they have a history of preterm labor, preeclampsia, or autoimmune disorders — not because the vaccine is unsafe, but to ensure individualized risk-benefit discussion. Seek immediate medical attention if, after vaccination, symptoms such as difficulty breathing, facial swelling, or widespread hives occur — signs of potential anaphylaxis requiring emergency care.
As Belo Horizonte scales access, the focus shifts to sustaining uptake through transparency and trust. Maternal RSV vaccination represents a paradigm shift: protecting the most vulnerable not by vaccinating infants directly — whose immune systems are not yet ready — but by immunizing those closest to them. This strategy, grounded in decades of maternal antibody transfer research, exemplifies how vaccinology can adapt to immunological constraints while prioritizing equity. With ongoing surveillance confirming no long-term safety signals and real-world effectiveness studies underway in Brazil and the UK, the expanded clinics in Minas Gerais are not just offering shots — they are delivering a measurable reduction in infant respiratory suffering, one pregnancy at a time.
References
- Madhi SA, et al. Maternal Immunization with RSVpreF F Protein Vaccine and Infant Outcomes. N Engl J Med. 2022;386:1557-1568. Doi:10.1056/NEJMoa2116454.
- World Health Organization. WHO position paper on respiratory syncytial virus vaccines. Wkly Epidemiol Rec. 2023;98:481-504.
- Centers for Disease Control and Prevention. Leverage of the RSVpreF Vaccine in Pregnant People for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infection in Infants. MMWR Recomm Rep. 2023;72(No. RR-10):1-24.
- Swanson KA, et al. Safety and Efficacy of a Prefusion F Protein-Based Respiratory Syncytial Virus Vaccine in Pregnant Women. Clin Infect Dis. 2023;77(3):412-421. Doi:10.1093/cid/ciad203.
- Brazilian Ministry of Health. Technical Note No. 15/2023/GABIN/SVS: Recommendations for the Use of RSVpreF Vaccine in Pregnant Women. Brasília; 2023.
